HER2 is among the most sensitive client proteins of HSP90 [78,79], and HSP90 inhibition mediates degradation of HER2, as well as PI3K and AKT in HER2-overexpressing cancer cells [80]. The gene discussed is HSP90AB1; the disease is cancer.